跳至主要内容
临床试验/NL-OMON55435
NL-OMON55435已完成3 期

Pre- versus Postoperative Accelerated Partial Breast Irradiation in early stage breast cancer patients - PAPBI-2

Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 150 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • * Female patients * 51 years
  • * cT1-2 (* 3 cm)
  • * Grade I or grade II (biopsy)
  • * Histologically proven invasive ductal adenocarcinoma
  • * Unifocal lesions on mammogram and MRI (small satellite lesions adjacent to
  • the tumor are accepted as long as it is suitable for local excision to be
  • determined by the participating centre)
  • * WHO performance * 2
  • * Life expectancy * 5 years
  • * Written informed consent

排除标准

  • * Distant metastases
  • * Lobular invasive carcinomas
  • * Pure DCIS without invasive tumor
  • * Grade III in biopsy
  • * Triple negative tumors
  • * HER2neu positive tumors
  • * Lymphvascular invasion in biopsy
  • * pN+ (Micro- or macrometastases
  • * Multicentric / multifocal disease on mammogram or MRI
  • * Diffuse calcifications on mammogram (Birads 3, 4 or 5)
  • * Prior treatment for the protocol tumor (no surgery, no neoadjuvant
  • chemotherapy or neoadjuvant hormonal therapy, no previous radiotherapy)
  • * Previous contralateral breast cancer:
  • * Other neoplasms in the last 5 years with the exception of:
  • - Basal cell carcinoma of the skin
  • - Adequately treated carcinoma in situ of the cervix
  • * Planned oncoplastic resection with tissue displacement
  • * No social security affiliation/health insurance
  • * Participation in another clinical trial that interferes with the locoregional
  • treatment of this protocol
  • * It is expected that dosimetric constraints cannot be met, ie, lung/heart
  • constraints (see 6.1.5), or if the ratio PTV/ ipsilateral breast >30%

研究者

发起方
Antoni van Leeuwenhoek Ziekenhuis

相似试验